Quintrio
Home

SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

Medpace Holdings, Inc. Common Stock

MEDP

Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Last trade $646.87
Day change -$1.33 (-0.21%)
Day range $612.46 – $669.91
Volume 85,232
Market cap $18.13B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$18.13B
Price / earnings
35.01×
Price / book
31×
Price / sales
6.39×
EV / sales
6.14×
EV / EBITDA
27.47×

Profitability

Earnings per share
$18.51
Return on assets
22.49%
Return on equity
88.53%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
0.83×
Quick ratio
0.83×
Cash ratio
0.47×

Cash flow

Price / cash flow
25.08×
Price / free cash flow
27.16×
Free cash flow
$667.63M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MEDP, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$716M$707.33M$706.6M$708.45M$659.9M$603.31M$558.57M$536.59M
Cost of revenue$492.12M$505.69M$510.28M$503.13M$462.96M$423.3M$380.22M$358.27M
Gross profit$223.89M$201.64M$196.33M$205.32M$196.94M$180.01M$178.35M$178.32M
Selling, general and administrative$51.77M$48.1M$47.92M$44.92M$48.08M$46.66M$57.9M$45.43M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$58.35M$54.81M$54.82M$52.05M$55.13M$53.68M$64.83M$52.94M
Operating income$165.54M$146.82M$141.5M$153.27M$141.81M$126.34M$113.52M$125.38M
Interest expense$5.35M$0$0$0$1.52M$0$0$0
Income before taxes$170.91M$151.66M$147.59M$156.83M$142.84M$124.54M$118.17M$133.88M
Income taxes$33.45M$30.3M$23.72M$21.7M$31.7M$34.28M$3.58M$16.86M
Net income$137.46M$121.36M$123.87M$135.13M$111.14M$90.26M$114.6M$117.02M
Net income attributable to common shareholders$137.46M$121.36M$123.87M$135.13M$111.14M$90.26M$114.6M$117.02M
EBITDA$172.12M$153.53M$148.41M$160.4M$148.86M$133.35M$120.45M$132.88M
Basic earnings per share$4.92$4.31$4.35$4.78$3.95$3.16$3.77$3.78
Diluted earnings per share$4.84$4.25$4.28$4.67$3.86$3.10$3.67$3.67

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Are Options Traders Betting on a Big Move in Medpace Stock?

Medpace Holdings (MEDP) is drawing attention from options traders due to high implied volatility in its December 2026 $370 put options, suggesting market expectations for significant price movement. Despite the volatility, the company maintains a Zacks Rank #2 (Buy) rating with analysts raising earnings estimates for the current quarter from $4.64 to $4.82 per share over the last 30 days.

Zacks Investment Research

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)

Medpace (MEDP) is highlighted as a compelling growth stock opportunity, combining a Growth Score of B with a Zacks Rank #2 (Buy). The company demonstrates strong fundamentals including 18.2% projected EPS growth (above the 14% industry average), robust cash flow growth of 10.5% year-over-year, and positive earnings estimate revisions with a 3% surge over the past month.

Zacks Investment Research

ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down

Alcon Inc. (ALC) reported Q3 2026 core EPS of 91 cents, beating estimates by 2.3%, but net sales of $2.72 billion missed consensus by 0.6%. While Vision Care and Equipment segments showed strength, Implantables sales declined 2% due to competitive pressures. The company narrowed its 2026 guidance, expecting 6% constant-currency net sales growth and 12-14% core EPS growth, which weighed on investor sentiment.

Zacks Investment Research

NTRA Q3 Loss Wider Than Expected, Revenues Beat, '26 Sales View Up

Natera (NTRA) reported Q3 2026 results with adjusted EPS loss of 39 cents missing estimates, but revenues of $794 million beat expectations with 34.1% year-over-year growth. Oncology test volumes surged 60.9% and MRD testing showed strong momentum. The company raised its 2026 revenue guidance to $3.005-$3.035 billion and maintained positive cash flow expectations, though operating losses remain a concern.

Zacks Investment Research

If You Invested $1000 in Medpace a Decade Ago, This is How Much It'd Be Worth Now

A $1,000 investment in Medpace (MEDP) made in November 2016 would be worth $20,503.07 as of November 6, 2026, representing a 1,950.31% gain. The clinical contract research organization has demonstrated strong performance with $2.5 billion in fiscal 2025 revenue (up 20% YoY), record third-quarter awards, and a $3.17 billion backlog. However, analysts note revenue growth has moderated, cancellations remain unpredictable, and planned campus costs could restrain 2027 profitability.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.